Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckRobert L. Ferris, Maura L. Gillison, George R. Blumenschein et al.|New England Journal of Medicine|2016Cited by 5.1k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expressionRobert L. Ferris, Maura L. Gillison, George R. Blumenschein et al.|Oral Oncology|2018Cited by 802
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trialKevin J. Harrington, J. Guigay, Robert L. Ferris et al.|The Lancet Oncology|2017Cited by 431
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLCChristian Manegold, Everett E. Vokes|Journal of Thoracic Oncology|2016Cited by 253
Quantitative Imaging Study of Extent of Surgical Resection and Prognosis of Malignant AstrocytomasAndrew Kowalczuk, Robert Wollman, R. Loch Macdonald et al.|Neurosurgery|1997Cited by 217